JO3063B1 - Novel compound and methods for its production - Google Patents
Novel compound and methods for its productionInfo
- Publication number
- JO3063B1 JO3063B1 JOP/2012/0053A JOP20120053A JO3063B1 JO 3063 B1 JO3063 B1 JO 3063B1 JO P20120053 A JOP20120053 A JO P20120053A JO 3063 B1 JO3063 B1 JO 3063B1
- Authority
- JO
- Jordan
- Prior art keywords
- production
- methods
- novel compound
- compound
- infecfion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Abstract
There is provided inter alia a compound of formula (I):for use in treatment of viral infecfion or as an immunosuppressant.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105293.3A GB201105293D0 (en) | 2011-03-29 | 2011-03-29 | Novel compounds and methods for their production |
| GBGB1113629.8A GB201113629D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
| GBGB1202060.8A GB201202060D0 (en) | 2012-02-07 | 2012-02-07 | Novel compounds and methods for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3063B1 true JO3063B1 (en) | 2017-03-15 |
Family
ID=46001313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2012/0053A JO3063B1 (en) | 2011-03-29 | 2012-03-12 | Novel compound and methods for its production |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9139613B2 (en) |
| EP (2) | EP2691413B1 (en) |
| JP (2) | JP6118793B2 (en) |
| KR (2) | KR101868084B1 (en) |
| CN (3) | CN107417766A (en) |
| AR (1) | AR085724A1 (en) |
| AU (2) | AU2012235880B2 (en) |
| BR (2) | BR112013024965A2 (en) |
| CA (2) | CA2830827C (en) |
| CL (2) | CL2013002740A1 (en) |
| CY (2) | CY1116318T1 (en) |
| DK (2) | DK2691412T3 (en) |
| EA (2) | EA023848B1 (en) |
| ES (2) | ES2533437T3 (en) |
| HK (2) | HK1189236A1 (en) |
| HR (2) | HRP20150187T1 (en) |
| IL (2) | IL228509B (en) |
| JO (1) | JO3063B1 (en) |
| MX (2) | MX345351B (en) |
| MY (2) | MY170637A (en) |
| PL (2) | PL2691412T3 (en) |
| PT (2) | PT2691413E (en) |
| RS (2) | RS53964B1 (en) |
| SG (2) | SG193568A1 (en) |
| SI (2) | SI2691412T1 (en) |
| TW (1) | TWI525098B (en) |
| UY (1) | UY33993A (en) |
| WO (2) | WO2012131371A1 (en) |
| ZA (2) | ZA201307149B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2541853T3 (en) | 2010-02-09 | 2015-07-27 | Neurovive Pharmaceutical Ab | Sangliferin based compounds |
| JO3063B1 (en) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | Novel compound and methods for its production |
| CN103130734A (en) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | Method of synthesizing 1, 2-morpholine hydrochloride |
| CN105695541B (en) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | A kind of isolation and purification method of antibiotic NVP018 intermediate |
| KR20180036522A (en) | 2016-09-30 | 2018-04-09 | (주)나노믹스 | Stilbene derivatives and preparation method thereof |
| CA3043131A1 (en) | 2016-11-18 | 2018-05-24 | Neurovive Pharmaceutical Ab | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
| CN112410353B (en) * | 2019-08-23 | 2023-01-24 | 上海医药工业研究院 | fkbS gene, genetic engineering bacterium containing fkbS gene, and preparation method and application of fkbS gene |
| CN115028681B (en) * | 2022-08-11 | 2022-11-15 | 中国科学院微生物研究所 | Chimeric compound for degrading cyclophilin A and preparation method and application thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (en) | 1995-07-04 | 1999-09-08 | Sandoz Ag | A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES |
| AU2006259348B2 (en) * | 2005-06-17 | 2010-07-22 | Novartis Ag | Use of sanglifehrin in HCV |
| CA2674296C (en) | 2007-01-04 | 2015-11-24 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| US8962329B2 (en) | 2008-09-24 | 2015-02-24 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Gene cluster |
| CN101691575B (en) * | 2008-09-24 | 2013-06-05 | 中国科学院上海有机化学研究所 | Biosynthetic gene cluster of sanglifehrin |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098805A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| ES2541853T3 (en) * | 2010-02-09 | 2015-07-27 | Neurovive Pharmaceutical Ab | Sangliferin based compounds |
| CN107090476B (en) * | 2010-12-20 | 2021-09-24 | 爱博利瓦有限公司 | Sanglifehrin derivatives and process for preparing the same |
| JO3063B1 (en) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | Novel compound and methods for its production |
-
2012
- 2012-03-12 JO JOP/2012/0053A patent/JO3063B1/en active
- 2012-03-28 AR ARP120101043A patent/AR085724A1/en unknown
- 2012-03-28 TW TW101110673A patent/TWI525098B/en not_active IP Right Cessation
- 2012-03-29 AU AU2012235880A patent/AU2012235880B2/en not_active Ceased
- 2012-03-29 MY MYPI2013701788A patent/MY170637A/en unknown
- 2012-03-29 CN CN201611126823.4A patent/CN107417766A/en active Pending
- 2012-03-29 CN CN201280026793.3A patent/CN103635484B/en active Active
- 2012-03-29 PT PT127165397T patent/PT2691413E/en unknown
- 2012-03-29 DK DK12716538T patent/DK2691412T3/en active
- 2012-03-29 EA EA201391399A patent/EA023848B1/en not_active IP Right Cessation
- 2012-03-29 KR KR1020137027773A patent/KR101868084B1/en active IP Right Grant
- 2012-03-29 PL PL12716538T patent/PL2691412T3/en unknown
- 2012-03-29 CN CN201280026190.3A patent/CN103619869B/en not_active Expired - Fee Related
- 2012-03-29 US US14/006,341 patent/US9139613B2/en active Active
- 2012-03-29 AU AU2012235961A patent/AU2012235961B2/en not_active Ceased
- 2012-03-29 RS RS20150162A patent/RS53964B1/en unknown
- 2012-03-29 PL PL12716539T patent/PL2691413T3/en unknown
- 2012-03-29 CA CA2830827A patent/CA2830827C/en not_active Expired - Fee Related
- 2012-03-29 PT PT127165389T patent/PT2691412E/en unknown
- 2012-03-29 JP JP2014501720A patent/JP6118793B2/en active Active
- 2012-03-29 EA EA201391396A patent/EA023907B1/en not_active IP Right Cessation
- 2012-03-29 MY MYPI2013701789A patent/MY170618A/en unknown
- 2012-03-29 SG SG2013070966A patent/SG193568A1/en unknown
- 2012-03-29 ES ES12716538.9T patent/ES2533437T3/en active Active
- 2012-03-29 EP EP12716539.7A patent/EP2691413B1/en active Active
- 2012-03-29 DK DK12716539T patent/DK2691413T3/en active
- 2012-03-29 CA CA2830831A patent/CA2830831C/en not_active Expired - Fee Related
- 2012-03-29 JP JP2014501719A patent/JP6118792B2/en not_active Expired - Fee Related
- 2012-03-29 UY UY0001033993A patent/UY33993A/en not_active Application Discontinuation
- 2012-03-29 MX MX2013011043A patent/MX345351B/en active IP Right Grant
- 2012-03-29 SI SI201230145T patent/SI2691412T1/en unknown
- 2012-03-29 US US13/433,944 patent/US9090657B2/en active Active
- 2012-03-29 KR KR1020137028095A patent/KR101911484B1/en active IP Right Grant
- 2012-03-29 ES ES12716539.7T patent/ES2533438T3/en active Active
- 2012-03-29 RS RS20150161A patent/RS53963B1/en unknown
- 2012-03-29 WO PCT/GB2012/050700 patent/WO2012131371A1/en active Application Filing
- 2012-03-29 EP EP12716538.9A patent/EP2691412B1/en active Active
- 2012-03-29 SI SI201230146T patent/SI2691413T1/en unknown
- 2012-03-29 WO PCT/GB2012/050707 patent/WO2012131377A1/en active Application Filing
- 2012-03-29 MX MX2013011051A patent/MX345352B/en active IP Right Grant
- 2012-03-29 SG SG2013070974A patent/SG193569A1/en unknown
- 2012-03-29 BR BR112013024965A patent/BR112013024965A2/en not_active Application Discontinuation
- 2012-03-29 BR BR112013024974A patent/BR112013024974A2/en not_active Application Discontinuation
-
2013
- 2013-09-17 IL IL228509A patent/IL228509B/en active IP Right Grant
- 2013-09-17 IL IL228508A patent/IL228508B/en active IP Right Grant
- 2013-09-23 ZA ZA2013/07149A patent/ZA201307149B/en unknown
- 2013-09-25 CL CL2013002740A patent/CL2013002740A1/en unknown
- 2013-09-25 CL CL2013002739A patent/CL2013002739A1/en unknown
- 2013-09-26 ZA ZA2013/07231A patent/ZA201307231B/en unknown
-
2014
- 2014-02-13 HK HK14101335.6A patent/HK1189236A1/en not_active IP Right Cessation
- 2014-02-13 HK HK14101336.5A patent/HK1189237A1/en not_active IP Right Cessation
-
2015
- 2015-02-17 HR HRP20150187TT patent/HRP20150187T1/en unknown
- 2015-02-17 HR HRP20150184TT patent/HRP20150184T1/en unknown
- 2015-02-27 CY CY20151100207T patent/CY1116318T1/en unknown
- 2015-03-06 CY CY20151100236T patent/CY1116186T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3063B1 (en) | Novel compound and methods for its production | |
| PH12015502839B1 (en) | Antiviral compounds | |
| AU2012324803A8 (en) | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | |
| MD20140047A2 (en) | Protein kinase inhibitors | |
| MX341456B (en) | Amino-quinolines as kinase inhibitors. | |
| MX2013015308A (en) | Proteasome inhibitors and processes for their preparation, purification and use. | |
| PH12014501258A1 (en) | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof | |
| TN2013000400A1 (en) | Imidazopyridazines as akt kinase inhibitors | |
| MX2014002936A (en) | Novel betulinic acid derivatives with antiviral activity. | |
| MX2020005533A (en) | Novel process for making compounds for use in the treatment of cancer. | |
| MX2013008340A (en) | Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer. | |
| MX349373B (en) | Novel pyrazine derivatives. | |
| MX2013010050A (en) | Proteasome inhibitor delanzomib for use in the treatment of lupus. | |
| MX2013005819A (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture. | |
| GB201107985D0 (en) | Process | |
| IN2014MN00850A (en) | ||
| MX348758B (en) | Sanglifehrin derivatives and methods for their production. | |
| MX359399B (en) | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS. | |
| IN2014DN10658A (en) | ||
| MX348841B (en) | Pyrimidooxazocine derivatives as mtor - inhibitors. | |
| MX2013005825A (en) | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture. | |
| MY160625A (en) | Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation | |
| TN2013000128A1 (en) | Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation |